Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination-Reference-Cited by-同舟云学术

Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination

Published:2022-09 Issue: Volume:122 Page:793-801
ISSN:1201-9712
Container-title:International Journal of Infectious Diseases
language:en
Short-container-title:International Journal of Infectious Diseases

Author:

Assawakosri Suvichada,Kanokudom Sitthichai,Chansaenroj Jira,Suntronwong Nungruthai,Auphimai Chompoonut,Nilyanimit Pornjarim,Vichaiwattana Preeyaporn,Thongmee Thanunrat,Duangchinda Thaneeya^ORCID,Chantima Warangkana,Pakchotanon Pattarakul^ORCID,Srimuan Donchida,Thatsanatorn Thaksaporn,Klinfueng Sirapa,Sudhinaraset Natthinee,Mongkolsapaya Juthathip,Wanlapakorn Nasamon^ORCID,Honsawek Sittisak,Poovorawan Yong

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference41 articles.

1. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant;Andrews;N Engl J Med,2022

2. Neutralizing activities against the Omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination;Assawakosri;J Infect Dis,2022

3. AstraZeneca PLC, First Quarter 2022 Results. https://www.astrazeneca.com/content/dam/az/PDF/2022/q1-2022/Q1-2022-results-announcement.pdf, 2022. (accessed 15 May 2022).

4. Serum neutralisation of the SARS-CoV-2 Omicron sublineage BA.2;Chen;Lancet Microbe,2022

5. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis;Choi;Nat Med,2021

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection;Vaccines;2024-02-10

2. Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination;Heliyon;2024-01

3. Homologous or heterologous COVID-19 vaccine schemes: comparison of immune responses and side effects;Diagnostic Microbiology and Infectious Disease;2023-10

4. Study of efficacy and antibody duration to fourth-dose booster of Ad5-nCoV or inactivated SARS-CoV-2 vaccine in Chinese adults: a prospective cohort study;Frontiers in Immunology;2023-09-06

5. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines;Expert Review of Vaccines;2023-07-07